Abstract
The Polycomb group (PcG) proteins regulate stem cell differentiation via the repression of gene transcription, and their deregulation has been widely implicated in cancer development. The PcG protein Enhancer of Zeste Homolog 2 (EZH2) works as a catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) by methylating lysine 27 on histone H3 (H3K27me3), a hallmark of PRC2-mediated gene repression. In skeletal muscle progenitors, EZH2 prevents an unscheduled differentiation by repressing muscle-specific gene expression and is downregulated during the course of differentiation. In rhabdomyosarcoma (RMS), a pediatric soft-tissue sarcoma thought to arise from myogenic precursors, EZH2 is abnormally expressed and its downregulation in vitro leads to muscle-like differentiation of RMS cells of the embryonal variant. However, the role of EZH2 in the clinically aggressive subgroup of alveolar RMS, characterized by the expression of PAX3-FOXO1 oncoprotein, remains unknown. We show here that EZH2 depletion in these cells leads to programmed cell death. Transcriptional derepression of F-box protein 32 (FBXO32) (Atrogin1/MAFbx), a gene associated with muscle homeostasis, was evidenced in PAX3-FOXO1 RMS cells silenced for EZH2. This phenomenon was associated with reduced EZH2 occupancy and H3K27me3 levels at the FBXO32 promoter. Simultaneous knockdown of FBXO32 and EZH2 in PAX3-FOXO1 RMS cells impaired the pro-apoptotic response, whereas the overexpression of FBXO32 facilitated programmed cell death in EZH2-depleted cells. Pharmacological inhibition of EZH2 by either 3-Deazaneplanocin A or a catalytic EZH2 inhibitor mirrored the phenotypic and molecular effects of EZH2 knockdown in vitro and prevented tumor growth in vivo. Collectively, these results indicate that EZH2 is a key factor in the proliferation and survival of PAX3-FOXO1 alveolar RMS cells working, at least in part, by repressing FBXO32. They also suggest that the reducing activity of EZH2 could represent a novel adjuvant strategy to eradicate high-risk PAX3-FOXO1 alveolar RMS.
Similar content being viewed by others
Introduction
Rhabdomyosarcomas (RMS) are heterogeneous highly malignant tumors, which account for 7–8% of all pediatric malignancies and over half of the soft-tissue sarcomas in children. RMS are classically subdivided in two major histotypes: embryonal (around 70–80%) and alveolar (around 20–30%), the latter often metastatic at diagnosis and showing a high risk of recurrence.1 In 70% of cases, alveolar RMS is characterized by the chromosomal translocation t(2;13) or t(1;13), resulting in PAX3-FOXO1 or PAX7/FOXO1 fusion oncoproteins that are considered the key negative prognostic molecular markers.1, 2 Current therapy regimens for high-risk RMS are often associated with significant morbidity in young patients and are often ineffective in preventing tumor progression. Although the expression of the muscle regulatory factor MyoD suggests their myogenic origin, the RMS cells fail to activate the differentiation program in response to physiological stimuli,3 and we and others have shown that enforced induction of myogenic differentiation leads to the loss of malignant phenotype in vitro and in vivo.3, 4, 5, 6
In vertebrates, Polycomb Group proteins form two main groups of multiprotein complexes, Polycomb Repressive Complex (PRC)-1 and PRC2.7 The enhancer of Zeste Homolog 2 (EZH2), the catalytic subunit of PRC2, methylates lysine 27 of histone H3 (H3K27me3), a hallmark of PRC2-mediated gene repression.8 EZH2 is downregulated during progenitor cell differentiation, being undetectable in adult specialized cells and tissues.8 Conversely, EZH2 is abnormally expressed in a wide range of tumors, with its level of expression being correlated with cancer aggressiveness.8 In undifferentiated muscle cells, EZH2-mediated trimethylation of H3K27 contributes to maintaining the chromatin of muscle genes in a conformation repressive for transcription, supporting the self-renewal and proliferation of progenitor cells.9, 10, 11, 12, 13 At the onset of differentiation, downregulation of EZH2 allows a chromatin conformation permissive for transcription of differentiation genes.11, 12, 13 These data highlight the importance of EZH2 in controlling the balance between proliferation and differentiation of myogenic progenitors.
A number of reports have shown that aberrant overexpression of EZH2 in human cancers is often associated with poor prognosis.14, 15, 16, 17, 18 EZH2 is expressed in undifferentiated stem-like cancer cells and promotes cancer cell proliferation and metastasis formation by repressing several tumor suppressor genes.15, 19, 20, 21, 22, 23, 24 Notably, its molecular or pharmacological inhibition leads to the reversal of the malignant phenotype.24, 25, 26, 27, 28, 29 Collectively, these findings demonstrate a role of EZH2 as a potential prognostic marker and therapeutic target in cancer. We and others have recently reported that (i) as compared with the normal myoblasts and muscle tissues EZH2 is markedly overexpressed in RMS30, 31 and (ii) EZH2 downregulation in vitro leads to myogenic-like differentiation of an embryonal RMS cell line.32
However, the role of EZH2 in the aggressive PAX3-FOXO1 alveolar RMS cells has not been evaluated, and the effect of EZH2 inhibition on the tumorigenic phenotype remains to be tested.
In the present work, we sought to evaluate the response of alveolar RMS expressing the PAX3-FOXO1 oncoprotein to EZH2 inhibition and to dissect the underlying molecular mechanisms. We show that EZH2 depletion induced apoptosis of this subtype of RMS cells in part through the derepression of the EZH2 target gene F-box protein 32 (FBXO32), also known as Atrogin1/MAFbx. Consistently, FBXO32 depletion rescues, whereas its overexpression facilitates, the pro-apoptotic effect of EZH2 silencing.
Pharmacological inhibition of EZH2 using 3-Deazaneplanocin A (DZNep), an S-adenosyl-L-homocysteine hydrolase inhibitor that induces proteosome-mediated degradation of EZH2,25 or MC1945, a catalytic EZH2 inhibitor,33, 34 phenocopies EZH2 knockdown effects in vitro and hampers tumor xenograft growth in vivo. Altogether, these results identify a key function of EZH2 in promoting the survival of PAX3-FOXO1 alveolar RMS that involves, at least partially, the modulation of FBXO32 expression. They also indicate that affecting EZH2 activity either by depletion or by inactivation could provide an anticancer strategy in this high-risk subgroup of pediatric soft-tissue sarcomas.
Results
EZH2 protein levels are elevated in human PAX3-FOXO1 RMS primary samples and cell lines
We first evaluated whether, as we recently reported for EZH2 transcripts,30, 31 EZH2 protein levels were higher in PAX3-FOXO1 RMS tumor samples than in normal muscle tissue. EZH2 was studied using immunohistochemical analysis on 10 primary samples from PAX3-FOXO1-bearing alveolar RMS patients (Supplementary Table 1). EZH2 nuclear staining was detected in all the RMS specimens tested with median values ranging from 46 to 92% of positive nuclei per section, whereas normal muscles were negative (Figure 1a).
In line with data on primary tumors, EZH2 levels were higher in PAX3-FOXO1-positive alveolar RMS cell lines compared with control skeletal myoblasts (skeletal muscle cells) and the protein was mostly localized in the nuclear-enriched fractions (Figure 1b). Moreover, unlike what typically observed in myoblasts during differentiation, EZH2 levels were not modulated when RMS cells were incubated in differentiation culture conditions (low serum-containing medium) (Figure 1c).11 These findings imply that EZH2 expression and/or stability is deregulated in PAX3-FOXO1 alveolar RMS.
Downregulation of EZH2 prevents PAX3-FOXO1 RMS cell proliferation
As EZH2 expression sustains the proliferation of skeletal muscle precursors,9, 10, 11 we sought to examine the effect of EZH2 depletion on the proliferation potential of the PAX3-FOXO1 alveolar cell line RH30 cultured in a proliferation (growth) medium. Cells were subjected to a double round (24 h) of RNA interference with a previous validated pool of siRNAs against EZH2 to warrant efficient and sustained silencing and analyzed starting from 24 h after the first siRNA transfection. Interestingly, EZH2-depleted RH30 cells were unable to proliferate showing 12±3.5% survival 3 days after siRNA treatment (Figure 2a), as detected by trypan blue exclusion. EZH2 silencing was confirmed by western blot from 24 h onward (Figure 2b). Consistently, a global decrease in H3K27me3, but not in trimethylated Lys4 (H3K4me3), was detected at day 3 post-EZH2 siRNA transfection (Figure 2c). These results indicate that EZH2 has a role in the proliferation and survival of PAX3-FOXO1 alveolar RMS cells.
Knockdown of EZH2 promotes apoptosis of PAX3-FOXO1 alveolar RMS cells
EZH2 depletion in RH30 and RH4, another PAX3-FOXO1 alveolar RMS cell line, resulted in an increase of the percentage of cells in the subG1 cell-cycle phase compared with control siRNA cells (28±3 and 26±2%, respectively) (Figure 3a). This was associated with a decrease of the percentage of cells in G1 and S phases (30±6 and 11±3%, and 28±8 and 10±2%, respectively) and an increase by 20±3 and 18±5% of cells in G2 phase, respectively (Figure 3a). Among the pro-apoptotic genes derepressed upon EZH2 knockdown, we annotated the ubiquitin ligase FBXO32 (Atrogin 1/MFAbx) (Figures 3b and c), a tumor suppressor gene that is repressed by EZH2 in several tumor cell types.23 In contrast, the expression of another known pro-apoptotic EZH2 target gene BIM and that of BAX were not upregulated 48 h after EZH2 silencing in both cell lines (Figures 3b and c). Further, a decrease in Myogenin, MyoD and BCL2 protein levels and the appearance of a PARP-1-cleaved band in EZH2 siRNA cells compared with untreated or control siRNA cells (Figure 3c) indicated that the differentiation program was inhibited in favor of programmed cell death. The same effect was obtained in RH30 cells transfected with an siRNA targeting the 5′-UTR of EZH2 mRNA already used in our lab22 (Supplementary Figures 1a and b) or infected with a lentivirus expressing a short hairpin RNA against EZH2 (Supplementary Figures 1c and d). Altogether, these results rule out siRNA off-target effects.
Conversely to what was observed in PAX3-FOXO1 RMS cells, EZH2 siRNA-mediated depletion in skeletal muscle cells cultured in GM resulted in no modulation in FBXO32 transcript levels 48 h post siRNA treatment and was associated to sustained Myogenin mRNA and protein induction 48 and 96 h after silencing, respectively, compared with control siRNA cells (Supplementary Figures 2a and b). These findings confirm that the downregulation of EZH2 in normal myoblasts determine the triggering of a differentiation program as already reported.11, 35, 36
Finally, biochemical rescue experiments using a retroviral vector expressing the murine EZH2 (not targeted by the used EZH2 siRNA) abolished the upregulation of FBXO32 in EZH2-depleted RH30 cells (Supplementary Figure 3), indicating that the effect on FBXO32 expression is mediated by EZH2.
Derepression of FBXO32 has a role in apoptosis induced by EZH2 depletion in PAX3-FOXO1 alveolar RMS cells
In agreement with cell cycle results and with data in Supplementary Figure 1, EZH2 siRNA transfection increased the percentage of Annexin V-positive (apoptotic) cells from 14±3% in control siRNA to 46±5% and from 14±4 to 53±7% in RH30 and RH4 cells, respectively (Figures 4a and b). Despite transfection with control siRNA showed a slight cytotoxic effect compared with the untransfected condition, the difference between control and EZH2 siRNA treatments was remarkable. Conversely, no Annexin V-positive cell population was detected after EZH2 knockdown in skeletal muscle cells cultured in GM (Supplementary Figure 2c) highlighting, once more, the different effects of this approach in a diverse cellular microenvironment. Notably, the percentage of Annexin V-positive cells decreased by 50% in EZH2-depleted RMS cells co-transfected with an FBXO32 siRNA. In contrast, enforced overexpression of FBXO32 enhanced the apoptotic rate of about 40 and 65% in RH30 and RH4 cells after only 24 h of EZH2 knockdown (one round of silencing), respectively, while showed a slight effect in control siRNA cells (Figure 4c and Supplementary Figure 4). In agreement with what was observed after EZH2 silencing alone, this effect was associated with a decrease in MyoD and BCL2 (Figure 4d). Altogether, these data suggest that EZH2 supports the survival of PAX3-FOXO1 alveolar RMS cells at least in part by repressing FBXO32.
FBXO32 is directly targeted by EZH2 in PAX3-FOXO1 alveolar RMS cells
To confirm that FBXO32 is a target gene of EZH2 in our cell context, we performed chromatin immunoprecipitation assays to evaluate the binding of EZH2 and the H3K27me3 status on the FBXO32 promoter. Figure 5a shows that EZH2 recruitment decreased in EZH2-silenced RH30 cells as compared with control siRNA cells and this paralleled with a decrease in the levels of H3K27me3 at the Polycomb-dependent FBXO32 promoter, pointing to FBXO32 as a direct target of EZH2 in PAX3-FOXO1 alveolar RMS.
We previously reported that the Jumonji family member JARID2 cooperates with components of the PRC2 complex to regulate the H3K27me3 status on muscle regulatory genes in both embryonal and alveolar RMS cells. However, as shown in Supplementary Figure 5, JARID2 depletion by siRNA in PAX3-FOXO1 alveolar RMS cells did not affect H3K27me3 levels at the FBXO32 promoter, as already reported in other cell contexts.37, 38
Moreover, gene expression profiling data for 101 RMS previously described patient samples in the ITCC/CIT data set (Innovative Therapies for Children with Cancer/Carte d’Identité des Tumeurs)1 within the R2 online platform39 relative to publicly available Affymetrix expression profiling data for skeletal muscle samples (GSE9103), indicated that FBXO32 expression is much lower in RMS patient samples relative to skeletal muscle (Figure 5b), which is in direct contrast to EZH2 levels in RMS patient samples where EZH2 is overexpressed, as previously reported by our group.30 Finally, the analysis of the RMS patient sample set also showed a significant negative correlation between FBXO32 and EZH2 expression in RMS patient samples (R=−0.5, P=1.0e−07), once again indicating an inverse relationship between the levels of these two proteins that supports their functional interactions (Figure 5c).
Altogether, these results suggest that EZH2 directly regulates FBXO32 expression in PAX3-FOXO1 alveolar RMS cells and that it could also be involved in maintaining low expression levels in vivo.
Pharmacological inhibition of EZH2 prevents PAX3-FOXO1 RMS cell proliferation
As no direct catalytic EZH2 inhibitors were commercially available so far, we decided to pharmacologically inhibit EZH2 through two different approaches by treating cells with either (i) the S-adenosyl-L-homocysteine hydrolase inhibitor DZNep that indirectly inhibits EZH2 function mainly through degradation23, 24, 40 or (ii) a catalytic EZH2 inhibitor, MC1945, the more recent synthesized compound from a family of EZH2 inhibitors validated against a panel of histone methyltransferases.33, 34 In preliminary experiments, MC1945 behaved similarly but at lower doses to the family-related EZH2 catalytic inhibitor MC1948 (Supplementary Figure 6) previously used by our group to inhibit EZH2 in myoblasts41 and was therefore used in the subsequent assays. This experimental strategy was aimed at evaluating the ability of two different pharmacological types of inhibition to mimic the effects of siRNA-mediated depletion of EZH2 in vitro.
First, we characterized the effects of DZNep and MC1945 on the proliferation of PAX3-FOXO1-positive RMS cells and their capability to reduce H3K27marks. As shown in Figure 6a, 96 h treatment with 5 μM of either DZNep or MC1945 achieved a significant inhibition of cell proliferation compared with vehicle-treated or untreated cells, respectively. DZNep treatment resulted in the downregulation of EZH2 protein levels, whereas, in line with a role as a catalytic inhibitor, MC1945 treatment did not affect them. Importantly, both treatments resulted in a marked decrease in global levels of H3K27me3 (Figure 6b), as previously reported,25, 40, 41 whereas the levels of H3K9me3, another repressive mark, remained unchanged demonstrating that they act mainly through inhibition of EZH2-containing complexes at the used doses on the basis of previous reports for DZNep.24, 40, 42, 43, 44, 45 Consistently with EZH2 silencing-dependent effects, the appearance of apoptotic Annexin V-positive cells was seen in both DZNep- and MC1945-treated RH30 cells (Figure 6c) associated with transcriptional upregulation of FBXO32 gene and decreased Myogenin levels after 72 h (Figure 6d). Collectively, these observations indicate that pharmacological approaches either favoring the degradation or blocking the catalytic functions of EZH2 affect the proliferative potential of PAX3-FOXO1-positive alveolar RMS cells and mirror the effect of siRNA- and short hairpin RNA-mediated EZH2 depletion in derepressing FBXO32.
Pharmacological inhibition of EZH2 prevents PAX3-FOXO1 RMS tumor growth in vivo
We then evaluated whether inhibition of EZH2 functions through DZNep or MC1945 treatment could be a potential approach to treat PAX3-FOXO1 RMS also in vivo. Nude mice were inoculated with RH30 cells and, when tumors became palpable, intraperitoneally treated either with 2.5 mg/kg DZNep, a previously reported non-toxic dose in these conditions, or with a vehicle.19, 24 DZNep treatment resulted in a significant reduction in xenograft tumor volume (Figure 7a, left panels) and was associated with a decrease in the number of EZH2- and Ki67-positive cells (Figure 7b, upper panels). In agreement with in vitro results, a marked decrease in EZH2 protein levels was detected in DZNep-treated xenografts (Figure 7c). Similar results were obtained when mice were treated with 2.5 mg/kg of MC1945 (Figure 7a, right panels), which did not decrease EZH2 levels, as previously shown in vitro and confirmed here in xenografts using immunohistochemical analysis. An increase in TUNEL-positive cells was observed for both treatments consistent with the triggering of a pro-apoptotic program (Figure 7b, lower panels).
Collectively, our data provide evidence that EZH2 overexpression supports the survival of PAX3-FOXO1 alveolar RMS cells in vivo and suggest that targeting EZH2 might inspire novel therapeutic approaches to treat these high-risk alveolar RMS.
Discussion
We have previously shown that EZH2 mRNA is overexpressed in cell lines and primary samples of pediatric RMS.30, 31 Moreover, EZH2 knockdown has been shown to induce in vitro differentiation of cells of the embryonal RMS subtype.32 However, the effects of EZH2 downregulation in PAX3-FOXO1 alveolar RMS, clinically and molecularly distinct from the embryonal subtype1, 46, 47, 48 and considered as the highest-risk form of RMS,2 remained unknown. The present work was aimed at evaluating whether the modulation of EZH2 could affect tumorigenesis and at dissecting the molecular events that underlie EZH2 function in this subgroup of RMS. We show here that, in addition, the EZH2 protein levels are significantly higher in PAX3-FOXO1 alveolar RMS primary tissues as compared with the normal muscle tissues. Moreover, unlike what happens in normal myoblasts,11, 35 the differentiation cue due to cell culture in the low-serum medium is unable to modulate the EZH2 levels in PAX3-FOXO1 alveolar RMS cells, indicating a tumor-specific deregulation.
We show here that EZH2 depletion highly affects PAX3-FOXO1 RMS cell survival leading to apoptosis. We then provide evidence that this phenomenon is due, at least in part, to the derepression of the tumor suppressor gene FBXO32, already shown to be induced by EZH2 knockdown in cells of solid and blood cancers.23, 28, 40 Indeed, the simultaneous depletion of FBXO32 and EZH2 greatly reduced the apoptotic cell response, suggesting that EZH2 protects fusion-positive alveolar RMS cells from apoptosis in part by repressing FBXO32. Of note, FBXO32 derepression is associated with both a reduction in EZH2 recruitment and a decrease in H3K27me3 mark to the FBXO32 gene promoter, indicating that in our cell context EZH2 is recruited at this promoter and is enzymatically active to repress transcription, as already shown.23, 40 FBXO32, also known as Atrogin-1/MAFbx, is a muscle-specific E3 ligase involved in the massive protein degradation during muscle atrophy49 and is a FOXO1 target gene in atrophic muscle.50 However, there is no evidence for PAX3-FOXO1 directly regulating FBXO32 from analyses of ChIPseq data.51 Recently, it has been shown that, in rat myoblasts in vitro, expression of FBXO32, which is induced in these cells by serum starvation, facilitates myogenesis through the repression of myocardin.52 Intriguingly, both muscle atrophy and myogenesis involve apoptosis.53, 54, 55 Moreover, the evidence that a same factor could have opposite effects on skeletal muscle, depending on the context, is not new and exemplified by Myogenin that can promote differentiation or degradation in different muscle microenvironments.56 Therefore, the function of FBXO32 could be dependent from the molecular background and cellular normal or cancerous context.
Consistent with this idea, ectopic FBXO32 overexpression, although unable to induce per se consistent apoptosis, markedly enhances the cell death response in EZH2 knocked down cells, suggesting that it is required but insufficient to do so. It is, thus, conceivable that FBXO32 expression may need to coordinate with other molecular events activating a global apoptotic program to sustain apoptosis in PAX3-FOXO1 RMS cells. This hypothesis is supported by the concomitant protein downregulation of Myogenin and MyoD seen in EZH2-depleted cells, the latter known as directly targeted by FBXO32 for degradation in myoblasts,57, 58, 59 testifying the inability of our cells to undergo differentiation.32 In addition, a decrease in BCL2, which has been shown to be degraded in cardiomyoblasts through a mechanism that indirectly involves FBXO32,60 could support the triggering of an apoptotic process. These observations are in keeping with recently published data showing that the FBXO32 overexpression is not capable to induce apoptosis in the absence of chemotherapeutic drugs, although it is able to enhance the drug-induced pro-apoptotic effect in an ‘activated’ context.23
Interestingly, the modulation of JARID2, which can cooperate with components of the PRC2 at muscle-specific promoters in RMS, does not appear to affect H3K27me3 at the FBXO32 promoter suggesting that these two proteins do not cooperate to repress FBXO32 expression in RMS cells, as reported for other target genes.37, 38 However, an EZH2-dependent regulation of FBXO32 expression in the RMS context is consistent with the observation that FBXO32 transcript levels are inversely correlated with those of EZH2 in patients and significantly reduced as compared with the levels in their normal counterparts. In contrast, EZH2 modulation has different effects in embryonal vs fusion-positive alveolar RMS cells. The embryonal cell subtype, indeed, as observed for myoblasts (refs 11,35,36 and our Supplementary Figure 2), undergo myogenic-like differentiation after both EZH2 genetic silencing32 and pharmacological inhibition (unpublished observations from our group). Differences in the response to the same treatment of RMS variants are not unusual and are in agreement with both the different cytogenetic and molecular background of fusion-positive alveolar RMS also related to the expression of PAX-FOXO1 chimeric proteins.1, 2, 61, 62, 63, 64, 65
Collectively, our data suggest that in PAX3-FOXO1 alveolar RMS EZH2 supports tumor cell survival at least in part by repressing FBXO32.
Very recently, some highly specific EZH2 inhibitors have been discovered and published.26, 27, 29 In the attempt to evaluate the effect of pharmacologic inhibition of EZH2, we have used DZNep, which has been already shown to induce FBXO32 expression in cancer cells25, 28, 40, 66 in parallel with an EZH2 catalytic inhibitor, MC1945.33, 34 Both pharmacological treatments phenocopied the effects of genetic inhibition of EZH2 in vitro enhancing the apoptotic rate of fusion-positive alveolar RMS cells, upregulating FBXO32 and downregulating Myogenin. Moreover, even if higher concentrations of DZNep compared with those used in this study can affect histone methyltransferases other than EZH2,28 the decrease in H3K27me3, but not in H3K9me3 (another repressive transcriptional mark), observed after treatment with the two compounds suggests a selective function anti-EZH2.
Relevant under a translational point of view, in vivo studies showed that tumor growth is clearly impaired in animals in which the EZH2 function was blocked through the use of two different types of inhibitors, both leading to tumor cell apoptosis. These results suggest that EZH2 downregulation and/or inactivation could have an antitumor effect on PAX3-FOXO1-positive alveolar RMS in vivo being helpful in eradicating cancer cells, also in synergy with conventional chemotherapeutic compounds.
Growing evidence supports the use of epigenetic therapies in adult cancer patients.67 In addition, in pediatric tumors of different origin, histone methyltransferase could become targets for novel pharmacological therapies.68 In summary, the data presented here provide evidence that the overexpression of EZH2 has a fundamental role in supporting the malignant potential of PAX3-FOXO1 alveolar RMS cells and that its depletion and/or inactivation could provide a potential effective strategy to treat these pediatric high-risk RMS.
Materials and methods
Cell lines
Human PAX3-FOXO1 RMS cell lines RH30 and RH41 were described previously,6 and RH4 was a gift of C Ponzetto. Normal Human Skeletal Muscle cells (myoblasts) were obtained from PromoCell (Heidelberg, Germany). Supplementary methods describe cell lines and culture in detail.
Nuclear fraction enrichment
Cells were lysed and assayed as previously reported.6
Western blotting
Western blotting was performed on whole-cell lysates as previously described6 with antibodies described in Supplementary Methods.
Histone extraction
Cells were collected and washed twice with ice-cold phosphate-buffered saline (PBS) 1X supplemented with 5 mM sodium butyrate. After resuspension in triton extraction buffer (PBS, 0.5% triton X 100 (v/v)) containing 2 mM PMSF and 0.02% (w/v) NaN3 at a cell density of 107 cells/ml, cells were lysated on ice for 10 min. Lysates were centrifuged at 2000 r.p.m. for 10 min at 4 °C, and the pellets were washed in half volume of triton extraction buffer and centrifuged as before. Pellets were then resuspended in 0.2 N HCl at a cell density of 4 × 107 cells/ml and histones were extracted O/N at 4 °C. Samples were then centrifuged and supernatants were used for western blot analysis.
Transient RNA interference
Cells were sequentially transfected or co-transfected by two subsequent rounds (24 h) (100 nM final concentration each round), unless otherwise stated, using Oligofectamine (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s recommendations. ON-TARGETplus SMART pool siRNA against EZH2 (L-004218-00) or non-targeting siRNA (control; D-001206-13)15, 69, 70 (Dharmacon, Thermo Fisher Scientific, Lafayette, CO, USA) or siRNA against FBXO32 (either Hs02_00362139 or EHU155831 MISSION esiRNA, Sigma, St Louis, MO, USA) or non-targeting siRNA controls (Sigma) were used.
Real-time qRT-PCR
Total RNA was extracted using TRizol according to the manufacturer’s instructions (Invitrogen), and qRT-PCR was performed as described.6 Taqman gene assays for GAPDH, EZH2, Myogenin and MCK were from Applied Biosystems (Life Technologies, Carlsbad, CA, USA) (Hs99999905_m1, Hs01072232_m1, Hs00176490_m1). Murine Ezh2, FBXO32, BIM and BAX mRNAs were quantified through the SYBR-green method (Applied Biosystems) with primers previously reported23 or available on request.
Retroviral infections
The PMN-GFP retroviral vector expressing cMyc-tagged FBXO32 or control PMN-GFP empty vector was previously reported.23 The pMSCV-GFP retroviral vector (Addgene, Cambridge, MA, USA) expressing flag-tagged murine EZH2 or control pMSCV-GFP empty vector was from G Caretti. Phoenix ampho cells obtained from ATCC were cultured in DMEM supplemented with 10% FBS and transiently transfected using lipofectamine (Invitrogen, Life Technologies). Supernatant containing viral particles collected after 48 h was used to infect RMS cells O/N in the presence of 5 μg/ml of polybrene (two rounds of infection).
Cell proliferation, cell cycle and apoptosis assays
For proliferation, cells were collected and counted at the reported time points. For cell cycle analysis, cells were collected 24 h after the second round of silencing and treated as previously reported.6 For quantification of apoptosis, cells were stained in calcium-binding buffer with APC-conjugated Annexin V and 7-Aminoactinomycin D (7-AAD) using the Annexin V apoptosis detection kit (BD Pharmingen, San Diego, CA, USA), according to the manufacturer’s recommendations. Cells were analyzed by a fluorescence-activated cell sorting using a FACSCantoII equipped with FACSDiva 6.1 CellQuest software (Becton Dickinson Instrument, San Jose, CA, USA).
Gene expression analysis
Affymetrix U133A plus 2.0 profiling data from 101 previously described patient samples1 were analyzed using the R2 platform (Reference) using the 225328_at probe to detect FBXO32 and the 203358_s_at probe to detect EZH2 mRNA levels. The GSE9103 normal skeletal muscle data set within R2 was used for comparisons of FBXO32 levels between skeletal muscle and RMS patient samples.
Chromatin immunoprecipitation
The chromatin immunoprecipitation assay was performed as previously described.71 The following antibodies were used: anti-H3K27me3 (EMD Millipore Corporation, Billerica, MA, USA) and anti-EZH2 (Diagenode s.a. Liège, Belgium). Real-time PCR was performed on input samples and equivalent amounts of immunoprecipitated material with the SYBR Green Master Mix (Applied Biosystems) with primers spanning FBXO3223 and SMAD6 promoter regions as specified in the text (primer sequences available on request).
EZH2 inhibitory assay
The inhibitory assay for MC1945 against EZH2 has been already reported.34
Xenograft experiments and immunohistochemistry
Athymic 6-week-old female BALB/c nude mice (nu+\nu+) were purchased from Charles River Laboratories (Calco (Lecco), Italy). Procedures involving animals were conformed to the institutional guidelines that comply with the national and international laws and policies (EEC Council Directive 86\609, OJ L 358, 12 December 1987). Animals were inoculated subcutaneously into the posterior flanks with RH30 cell suspensions in PBS (5 × 106 cells) and, when the tumors became palpable, intraperitoneally injected (5 mice/group) either with DZNep (2.5 mg/kg) or normal saline (vehicle) or with MC1945 (2.5 mg/kg) or DMSO (vehicle) twice daily, 3 days per week for 3 weeks when mice were killed with no visible signs of toxicity.34, 72 Tumor volume was measured as reported.6 Sections from paraffin-embedded excised xenografts were stained with hematoxylin/eosin or immunohistochemically stained for EZH2 and Ki67 expression with antibodies and detection/acquisition methods reported below.
Immunohistochemistry on RMS primary tissues
Archival, de-identified formalin-fixed, paraffin-embedded PAX3-FOXO1 primary RMS and skeletal muscle control tissues were obtained from the Ospedale Pediatrico Bambino Gesù in Roma, University of Padova and Istituto Tumori di Milano, (Italy) after approval of the respective Institutional Review Boards. Clinicopathological characteristics of the cohort are reported in Supplementary Table 1. Histopathological features of the tumors were reviewed by a Pathologist of each Institution (RB, RA and PC) blinded to immunohistochemical results. Sections from RMS samples and four muscle tissue specimens were immunostained for EZH2 (Transduction Laboratories, BD, Franklin Lakes, NJ, USA)73 and Ki67 (Novocastra, Newcastle upon Tyne, UK), and EnVision System-HRP (Power vision Plus method, Zymed, San Francisco, CA, USA) or Biotinilated link (DAKO, Carpintera, CA, USA) secondary antibodies were used followed by staining with 3-amino-9-ethylcarbazolo or 3,3'-diaminobenzidine (chromogen kits, DAKO) and counterstaining with Gill’s hematoxylin (Bio-Optica, Milan, Italy). Negative controls were simultaneously stained either with isotype non-specific IgG or omitting the primary antibody. Each section was observed using an Eclipse E600 microscope (Nikon, Sesto Fiorentino, Firenze, Italy) and images were acquired through LUCIA software, version 4.81 (Nikon, Sesto Fiorentino, Firenze, Italy) with a Nikon Digital Camera DXM1200F.
Statistical analysis
The Student’s t-test was performed to assess the difference between various treatments. P<0.05 was defined as the statistic significance. Continuous variables were analyzed by the Mann−Whitney U-test or the Kruskal−Wallis test for pairwise or multiple comparisons, respectively. Statistical significance was set at a two-tailed P-value <0.05. All analyses were performed with SPSS 11.5.1 for Windows Package (SPSS, Inc., 1989−2002 and LEADTOOLS 1991−2000, LEAD Technologies, Inc, Chicago, IL, USA).
References
Williamson D, Missiaglia E, de Reynies A, Pierron G, Thuille B, Palenzuela G et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010; 28: 2151–2158.
Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 2012; 30: 1670–1677.
Puri PL, Wu Z, Zhang P, Wood LD, Bhakta KS, Han J et al. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev 2000; 14: 574–584.
Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008; 14: 369–381.
Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 2009; 119: 2366–2378.
Raimondi L, Ciarapica R, De Salvo M, Verginelli F, Gueguen M, Martini C et al. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo. Cell Death Differ 2012; 19: 871–881.
Lanzuolo C, Orlando V . Memories from the polycomb group proteins. Annu Rev Genet 2012; 46: 561–589.
Margueron R, Reinberg D . The Polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343–349.
Woodhouse S, Pugazhendhi D, Brien P, Pell JM . Ezh2 maintains a key phase of muscle satellite cell expansion but does not regulate terminal differentiation. J Cell Sci 2012; 126: 565–579.
Juan AH, Derfoul A, Feng X, Ryall JG, Dell'Orso S, Pasut A et al. Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells. Genes Dev 2011; 25: 789–794.
Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V . The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 2004; 18: 2627–2638.
Serra C, Palacios D, Mozzetta C, Forcales SV, Morantte I, Ripani M et al. Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation. Mol Cell 2007; 28: 200–213.
Mousavi K, Zare H, Wang AH, Sartorelli V . Polycomb protein Ezh1 promotes RNA polymerase II elongation. Mol Cell 2012; 45: 255–262.
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624–629.
Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K . EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo J 2003; 22: 5323–5335.
Raaphorst FM, Meijer CJ, Fieret E, Blokzijl T, Mommers E, Buerger H et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003; 5: 481–488.
Kalushkova A, Fryknas M, Lemaire M, Fristedt C, Agarwal P, Eriksson M et al. Polycomb target genes are silenced in multiple myeloma. PLoS One 2010; 5: e11483.
Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF et al. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 2010; 31: 1576–1583.
Kemp CD, Rao M, Xi S, Inchauste S, Mani H, Fetsch P et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res 2011; 18: 77–90.
Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67: 10657–10663.
Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009; 69: 9211–9218.
Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q . Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ 2010; 17: 801–810.
Wu Z, Lee ST, Qiao Y, Li Z, Lee PL, Lee YJ et al. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ 2011; 18: 1771–1779.
Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei JS et al. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res 2011; 72: 315–324.
Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009; 114: 2733–2743.
Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 2012; 109: 21360–21365.
Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8: 890–896.
Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E et al. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clin Cancer Res 2012; 18: 6227–6238.
McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108–112.
Walters ZS, Villarejo-Balcells B, Olmos D, Buist TWS, Missiaglia E, Allen R et al. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene 2014; 33: 1148–1157.
Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R et al. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 2009; 8: 172–175.
Marchesi I, Fiorentino FP, Rizzolio F, Giordano A, Bagella L . The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation. Cell Cycle 2012; 11: 3828–3836.
Mai A, Valente S, Cheng D, Perrone A, Ragno R, Simeoni S et al. Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors. ChemMedChem 2007; 2: 987–991.
Valente S, Lepore I, Dell'Aversana C, Tardugno M, Castellano S, Sbardella G et al. Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells. Biochimie 2012; 94: 2308–2313.
Wong CF, Tellam RL . MicroRNA-26a targets the histone methyltransferase enhancer of zeste homolog 2 during myogenesis. J Biol Chem 2008; 283: 9836–9843.
Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V . Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol Cell 2009; 36: 61–74.
Shen X, Kim W, Fujiwara Y, Simon MD, Liu Y, Mysliwiec MR et al. Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell 2009; 139: 1303–1314.
Peng JC, Valouev A, Swigut T, Zhang J, Zhao Y, Sidow A et al. Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 2009; 139: 1290–1302.
Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans ME et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci USA 2012; 109: 19190–19195.
Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21: 1050–1063.
Palacios D, Mozzetta C, Consalvi S, Caretti G, Saccone V, Proserpio V et al. TNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 2010; 7: 455–469.
Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009; 8: 1579–1588.
Gannon OM, Merida de Long L, Endo-Munoz L, Hazar-Rethinam M, Saunders NA . Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation. Clin Cancer Res 2012; 19: 428–441.
Benoit YD, Laursen KB, Witherspoon MS, Lipkin SM, Gudas LJ . Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells. J cell physiol 2012; 228: 764–772.
Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, Yu Y et al. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res 2012; 18: 4201–4212.
Wachtel M, Dettling M, Koscielniak E, Stegmaier S, Treuner J, Simon-Klingenstein K et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004; 64: 5539–5545.
Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H et al. Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol 2009; 174: 550–564.
Ren YX, Finckenstein FG, Abdueva DA, Shahbazian V, Chung B, Weinberg KI et al. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 2008; 68: 6587–6597.
Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL . Atrogin-1,a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001; 98: 14440–14445.
Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399–412.
Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010; 70: 6497–6508.
Jiang Y, Singh P, Yin H, Zhou YX, Gui Y, Wang DZ et al. Opposite roles of myocardin and atrogin-1 in L6 myoblast differentiation. J cell physiol 2013; 228: 1989–1995.
Ogata T, Machida S, Oishi Y, Higuchi M, Muraoka I . Differential cell death regulation between adult-unloaded and aged rat soleus muscle. Mech ageing Dev 2009; 130: 328–336.
Fernando P, Kelly JF, Balazsi K, Slack RS, Megeney LA . Caspase 3 activity is required for skeletal muscle differentiation. Proc Natl Acad Sci USA 2002; 99: 11025–11030.
Hunt LC, Upadhyay A, Jazayeri JA, Tudor EM, White JD . Caspase-3, myogenic transcription factors and cell cycle inhibitors are regulated by leukemia inhibitory factor to mediate inhibition of myogenic differentiation. Skelet muscle 2011; 1: 17.
Moresi V, Williams AH, Meadows E, Flynn JM, Potthoff MJ, McAnally J et al. Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell 2010; 143: 35–45.
Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, Leibovitch SA . Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J biol chem 2005; 280: 2847–2856.
Okada A, Ono Y, Nagatomi R, Kishimoto KN, Itoi E . Decreased muscle atrophy F-box (MAFbx) expression in regenerating muscle after muscle-damaging exercise. Muscle Nerve 2008; 38: 1246–1253.
Lagirand-Cantaloube J, Cornille K, Csibi A, Batonnet-Pichon S, Leibovitch MP, Leibovitch SA . Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo. PLoS One 2009; 4: e4973.
Xie P, Guo S, Fan Y, Zhang H, Gu D, Li H . Atrogin-1/MAFbx enhances simulated ischemia/reperfusion-induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK activation. J biol chem 2009; 284: 5488–5496.
Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ . Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. J Clin Oncol 2010; 28: 1240–1246.
Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 2008; 365: 568–574.
Ramirez-Peinado S, Alcazar-Limones F, Lagares-Tena L, El Mjiyad N, Caro-Maldonado A, Tirado OM et al. 2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Cancer Res 2011; 71: 6796–6806.
Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 2012; 18: 3780–3790.
Lee MH, Jothi M, Gudkov AV, Mal AK . Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. Cancer Res 2011; 71: 3921–3931.
Momparler RL, Idaghdour Y, Marquez VE, Momparler LF . Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation. Leuk Res 2012; 36: 1049–1054.
Boumber Y, Issa JP . Epigenetics in cancer: what's the future? Oncology 2012; 25: 220–226 228.
Lawlor ER, Thiele CJ . Epigenetic changes in pediatric solid tumors: promising new targets. Clin Cancer Res 2012; 18: 2768–2779.
Fan T, Jiang S, Chung N, Alikhan A, Ni C, Lee CC et al. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res 2011; 9: 418–429.
Chng KR, Chang CW, Tan SK, Yang C, Hong SZ, Sng NY et al. A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. Embo J 2012; 31: 2810–2823.
Simone C, Forcales SV, Hill DA, Imbalzano AN, Latella L, Puri PL . p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci. Nat genet 2004; 36: 738–743.
Bray M, Driscoll J, Huggins JW . Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 2000; 45: 135–147.
Vekony H, Raaphorst FM, Otte AP, van Lohuizen M, Leemans CR, van der Waal I et al. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. J Clin Pathol 2008; 61: 744–749.
Acknowledgements
We thank E Giorda for fluorescence-activated cell sorting analysis. Myogenin (Wright WE) and MHC (Fishman DA) antibodies were obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biology, Iowa City, IA 52242, USA. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC, 10338) and Italian Ministry of Health Ricerca Corrente (RR); Association for International Cancer Research (AICR-UK, 12-0168) (DP); AIRC 5 per mille (FL); NIH Intramural Research Program, National Cancer Institute, CCR (VEM); Cancer Research UK (C5066/A10399) (ZSW); Sarcoma UK (ZSW, JS); Progetto IIT-Sapienza A2, FIRB RBFR10ZJQT and FP7 Project BLUEPRINT/282510 (AM). SS is a Chercheur National of the Fonds de la Recherche en Santé du Quebec.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
About this article
Cite this article
Ciarapica, R., De Salvo, M., Carcarino, E. et al. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene 33, 4173–4184 (2014). https://doi.org/10.1038/onc.2013.471
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.471
Keywords
This article is cited by
-
Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells
Clinical Epigenetics (2023)
-
E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor
Oncogene (2021)
-
The transcription elongation factor TCEA3 induces apoptosis in rhabdomyosarcoma
Cell Death & Disease (2020)
-
Rhabdomyosarcoma
Nature Reviews Disease Primers (2019)
-
TBX3 represses TBX2 under the control of the PRC2 complex in skeletal muscle and rhabdomyosarcoma
Oncogenesis (2019)